Prespecified and post-hoc analyses of PD-1/PD-L1 inhibitors and novel targeted agents in first-line gastric cancer have found that patients enrolled in Asia have numerically improved PFS and OS compared with overall, global study populations [16–21]. The gene discussed is PDCD1; the disease is gastric cancer.